A new era in dementia research
For decades, Alzheimer disease has been one of the greatest challenges in medicine. Standard treatment has often focused on delaying symptoms rather than addressing the underlying disease process.
Research into targeted and potentially disease-modifying medicines has changed this landscape. New investigational treatments aim to influence pathological processes such as harmful protein accumulation in the brain.
Research at Promente
Promente focuses on mechanisms that have already been partly verified in previous phases. This is why many programs are phase III studies with defined safety data and preliminary clinical activity data.
Depending on the protocol, clinical trial participation may include advanced diagnostic procedures, specialist monitoring and investigational interventions under strict protocol conditions. It is not a guarantee of receiving an investigational medicine or changing disease course.
BIOGEN Celia 247AD201
One of the programs conducted at the center focuses on people with mild cognitive impairment and people in the early stage of Alzheimer disease.
For participants, the study may involve comprehensive diagnostics, contact with neurologists, psychogeriatricians and neuropsychologists, and careful monitoring throughout the study.